Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy

Immunotherapies have changed the medical management of metastatic melanoma. However, the early detection of patients who do not respond to these treatments is a key issue. We evaluated the quantitative monitoring of circulating tumor DNA (ctDNA) as an early predictor of response to anti-PD1. Patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Herbreteau, Guillaume, Vallée, Audrey, Knol, Anne-Chantal, Théoleyre, Sandrine, Quéreux, Gaelle, Varey, Emilie, Khammari, Amir, Dréno, Brigitte, Denis, Marc G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982743/
https://www.ncbi.nlm.nih.gov/pubmed/29861869
http://dx.doi.org/10.18632/oncotarget.25404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5982743/
https://www.ncbi.nlm.nih.gov/pubmed/29861869
http://dx.doi.org/10.18632/oncotarget.25404

Ejemplares similares